Skip to main content
    V

    Vyne Therapeutics Inc (VYNE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $28.56
    +3.11 (+12.22%)

    Market Cap: $19.07M

    Last updated: Jul 27, 2026 at 5:00 PM ET

    Vyne Therapeutics Inc (VYNE) Financials: Revenue, Profit and Cash Flow

    Updated May 15, 2026. Financial statements from company filings, amounts in US dollars.

    Vyne Therapeutics reported revenue of $570.00K for the fiscal year ended Dec 31, 2025, up 13.8% from the year before. That year, net income was -$26.48M with a net margin of -4646.1%, operating cash flow was -$33.12M and free cash flow was -$33.12M. The quarter ended Mar 31, 2026 had revenue of $86.00K and net income of -$3.58M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $674.00K, a compound annual decline of 1.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$570.00K+13.8%100.0%-5219.1%-4646.1%
    Dec 2024$501.00K+18.2%100.0%-8710.0%-7950.9%
    Dec 2023$424.00K-11.1%100.0%-6900.5%-6710.4%
    Dec 2022$477.00K-48.8%100.0%-7189.7%-4865.8%
    Dec 2021$931.00K-95.6%100.0%-4179.5%-7876.4%
    Dec 2020$20.99M+4638.8%93.4%-1203.0%-1217.4%
    Dec 2019$443.00K-87.7%100.0%-21641.8%-21484.9%
    Dec 2018$3.60M-21.5%100.0%-2083.2%-2062.9%
    Dec 2017$4.58M+579.8%100.0%-645.9%-634.6%
    Dec 2016$674.00KN/A100.0%-2126.4%-2087.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Mar 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$570.00K$501.00K$424.00K$477.00K$931.00K$20.99M$443.00K$3.60M$4.58M$674.00K
    Cost of revenue$0$0$0$0$0$1.39M$0$0$0$0
    Gross profit$570.00K$501.00K$424.00K$477.00K$931.00K$19.60M$443.00K$3.60M$4.58M$674.00K
    Research and development$19.24M$30.95M$16.31M$18.39M$19.54M$43.53M$51.20M$64.47M$29.01M$11.26M
    Operating income-$29.75M-$43.64M-$29.26M-$34.30M-$38.91M-$252.55M-$95.87M-$74.89M-$29.59M-$14.33M
    Net income-$26.48M-$39.83M-$28.45M-$23.21M-$73.33M-$255.57M-$95.18M-$74.16M-$29.08M-$14.07M
    EBITDA-$27.49M-$42.24M-$28.13M-$33.86MN/A-$252.21M-$94.08M-$73.63M-$29.52M-$14.17M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Revenue$86.00K$130.00K$169.00K$69.00K$202.00K$84.00K$121.00K$198.00K$98.00K$76.00K$114.00K$135.00K
    Gross profit$86.00K$130.00K$169.00K$69.00K$202.00K$84.00K$121.00K$198.00K$98.00K$76.00K$114.00K$135.00K
    Operating income-$3.82M-$5.22M-$7.79M-$7.54M-$9.20M-$12.77M-$13.09M-$10.40M-$7.38M-$6.83M-$6.23M-$10.32M
    Net income-$3.58M-$4.84M-$7.28M-$5.75M-$8.61M-$12.02M-$12.16M-$9.41M-$6.25M-$6.19M-$6.58M-$10.06M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $24.03M were 79.7% of total assets of $30.16M, against total liabilities of $2.40M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$30.16M$66.91M$97.69M$40.76M$67.05M$93.74M$81.16M$139.93M$66.87M$42.05M
    Current assets$30.01M$64.44M$95.96M$38.27M$63.19M$87.26M$76.41M$139.50M$63.86M$31.54M
    Cash and equivalents$24.03M$19.93M$30.62M$30.91M$42.25M$57.56M$43.76M$49.51M$10.21M$4.03M
    Total liabilities$2.40M$14.82M$8.95M$9.35M$18.41M$56.25M$63.58M$9.55M$14.57M$12.49M
    Short-term debtN/A$99.00K$115.00KN/A$349.00K$757.00K$700.00KN/A$3.36M$518.00K
    Long-term debtN/AN/AN/AN/AN/A$33.17M$32.73MN/AN/AN/A
    Shareholder equity$27.77M$52.09M$88.73M$31.20M$48.64M$37.49M$17.57M$130.38M-$57.03M-$29.44M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$25.87M$30.16M$36.13M$44.72M$56.42M$66.91M$76.20M$86.65M$91.68M$97.69M$19.27M$24.96M
    Total liabilities$1.24M$2.40M$4.04M$5.84M$12.29M$14.82M$12.66M$11.78M$8.31M$8.95M$7.76M$7.69M
    Cash and equivalents$24.63M$24.03M$19.35M$22.05M$28.21M$19.93M$16.27M$29.61M$19.07M$30.67M$15.45M$20.63M
    Shareholder equity$24.64M$27.77M$32.09M$38.88M$44.13M$52.09M$63.54M$74.87M$83.37M$88.73M$11.51M$17.27M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$33.12M-$33.97M-$25.34M-$29.20M-$56.37M-$137.08M-$73.39M-$68.66M-$28.22M-$2.27M
    Capital expenditures$0$117.00K$0$0$0$113.00K$1.06M$567.00K$27.00K$31.00K
    Free cash flow-$33.12M-$34.09M-$25.34M-$29.20M-$56.37M-$137.19M-$74.45M-$69.23M-$28.25M-$2.30M
    Dividends paidN/AN/AN/AN/A$294.00KN/A$33.87MN/AN/AN/A
    Investing cash flow$37.37M$23.36M-$57.35M$15.67M$1.03M$89.11M$41.87M-$11.76M-$15.09M-$37.52M
    Financing cash flow-$143.00K-$141.00K$82.39M$1.65M$39.78M$61.81M$47.95M$92.37M$49.49M$0
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow-$4.08M-$3.76M-$7.10M-$10.80M-$11.46M-$9.00M-$8.51M-$8.48M-$7.98M-$5.14M-$5.15M-$9.57M
    Capital expenditures$0$0$0$0$0$117.00K$0$0$0$0$0$0
    Free cash flow-$4.08M-$3.76M-$7.10M-$10.80M-$11.46M-$9.12M-$8.51M-$8.48M-$7.98M-$5.14M-$5.15M-$9.57M
    Last 12 quarters

    Frequently Asked Questions About VYNE

    What is Vyne Therapeutics' annual revenue?

    Vyne Therapeutics reported revenue of $570.00K for the fiscal year ended Dec 31, 2025.

    How fast is Vyne Therapeutics' revenue growing?

    Revenue was up 13.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 6.1%.

    Is Vyne Therapeutics profitable?

    No. Vyne Therapeutics reported net income of -$26.48M for the fiscal year ended Dec 31, 2025, with a net margin of -4646.1%.

    How much free cash flow does VYNE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$33.12M minus capital expenditures of $0 produced free cash flow of -$33.12M.

    How much debt does Vyne Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $24.03M.